Climb Bio, Inc. 8-K

What Happened Climb Bio, Inc. (CLYM) filed a complaint in Delaware Superior Court on December 31, 2025 against Alumis Inc. and its subsidiary Acelyrin, Inc. The suit challenges interpretation of an Asset Purchase Agreement dated January 11, 2024 between Acelyrin and Tenet Medicines, Inc. (a wholly owned Climb subsidiary). Climb seeks a declaratory judgment that its clinical-stage anti‑CD19 antibody candidate budoprutug is not a “Product” under the APA and that it therefore does not owe the milestone payment Alumis is seeking.

Key Details

• Complaint filed: December 31, 2025, in Delaware Superior Court.
• Parties named: Plaintiff — Climb Bio, Inc.; Defendants — Alumis Inc. and Acelyrin, Inc.
• Agreement at issue: Asset Purchase Agreement (APA) dated January 11, 2024 between Acelyrin and Tenet Medicines, Inc.
• Asset in dispute: budoprutug, a clinical‑stage anti‑CD19 monoclonal antibody for B‑cell mediated diseases; the Company disputes that it qualifies as a “Product” triggering a milestone.

Why It Matters This is a legal dispute over contractual interpretation that could affect whether Climb Bio must make a milestone payment under the APA. The complaint seeks a court declaration that the payment is not owed; the outcome could influence the company’s cash obligations and the rights tied to budoprutug. Investors should monitor future SEC updates and company disclosures for any changes in potential liabilities, settlements, or material impacts to development or commercialization plans.